DC-CIK免疫治疗联合化疗治疗血液恶性肿瘤的安全性和有效性分析  

Safety and Efficacy Analysis of DC-CIK Immunotherapy Combined with Chemotherapy for Hematological Malignancies

作　　者：熊华毅 余鹏 刘鲜梅 宋咏刚 胡祖权 曾柱 XIONG Huayi;YU Peng;LIU Xianmei;SONG Yonggang;HU Zuquan;ZENG Zhu(Immune Cells and Antibody Engineering Research Center in University of Guizhou Province/Key Laboratory of Biology and Medical Engineering,School of Biology and Engineering(School of Modern Industry for Health and Medicine),Guizhou Medical University,Guiyang,550025;Key Laboratory of Infectious Immune and Antibody Engineering of Guizhou Province,School of Basic Medical Sciences,Guizhou Medical University,Guiyang,550025)

机构地区：[1]贵州医科大学生物与工程学院(健康医药现代产业学院),贵州省高等学校免疫细胞与抗体工程研究中心/生物与医学工程重点实验室,贵阳550025 [2]贵州医科大学基础医学院,贵州省高等学校感染免疫与抗体工程重点实验室,贵阳550025

出　　处：《基因组学与应用生物学》2024年第3期504-521,共18页Genomics and Applied Biology

基　　金：国家自然科学基金项目(12132006);贵州省省级科技计划项目(黔科合平台人才[2021]5637号,黔科合基础-ZK[2023]一般402,黔科合平台人才[2016]5676和黔科合人才团队(2015)4021号)共同资助。

摘　　要：本研究旨在研究树突状细胞-细胞因子诱导的杀伤细胞(dendritic cell and cytokine-induced killer cell,DC-CIK)免疫治疗联合化疗治疗血液恶性肿瘤的临床疗效。本研究从PubMed、Web of Science、The Cochrane Library、Embase、CNKI、WanFang Data、SinoMed和VIP等数据库中,收集2000年1月至2023年2月发表的符合要求的随机对照研究,应用RevMan 5.4.1软件进行Meta分析。共纳入15篇文献,894例患者,包括686例骨髓瘤患者和208例白血病患者,其中DC-CIK免疫治疗联合化疗治疗组共451例,设置为联合治疗组,而单纯化疗组共443例,设置为化疗(对照)组。分析结果显示,联合治疗组在临床疗效、预后情况、生活质量及各项免疫指标(T淋巴细胞亚群分布和细胞因子分泌水平)等方面均优于化疗组,且不会给患者带来特异性的副作用。研究结果表明,DC-CIK免疫治疗联合化疗能够改善恶性血液肿瘤患者的免疫功能,增强机体的抗肿瘤能力,从而显著提高临床治疗的效果。The aim of this study is to investigate the clinical efficacy of dendritic cell and cytokine-induced killer cell(DC-CIK)immunotherapy in combination with chemotherapy in the treatment of hematological malignancies.This study collected eligible randomized controlled studies published from January 2000 to February 2023 from databases such as PubMed,Web of Science,The Cochrane Library,Embase,CNKI,WanFang Data,SinoMed and VIP database respectively by the same method,and applied RevMan 5.4.1 software for Meta-analysis.A total of 15 papers related to 894 patients,wherein 686 myeloma patients and 208 leukemia patients.There were 451 patients in the DC-CIK combined with chemotherapy treatment group were set as combination therapy group,while a total of 443 patients in the chemotherapy treatment group were set as the chemotherapy(control)group.The analysis results showed that the combination treatment group was better than the chemotherapy group in terms of clinical efficacy,prognosis,survival quality and various immune indexes(T lymphocyte subpopulation distribution and cytokine secretion level),and did not cause specific side effects to patients.This study demonstrates that DC-CIK immunotherapy combined with chemotherapy can significantly improve the clinical efficacy of patients with malignant hematological tumors,improve their immune function and enhance the anti-tumor ability of the body.

关 键 词：树突状细胞-细胞因子诱导的杀伤细胞 联合治疗 血液恶性肿瘤 META分析 

分 类 号：R733[医药卫生—肿瘤]